ipamorelin half-life in humans pharmacokinetics Biological Plasma GH levels versus time

It has never completed Phase III clinical trials and remains classified as a research compound

ThinWorks provides CJC 1295 Ipamorelin Peptide Therapy in Palm Beach Gardens , Florida, to help with health and fitness goals

(JCEM 2006) They documented a 2- to 10-fold increase in plasma GH (dose-dependent), a 1.5- to 3-fold increase in IGF-1 for 9-11 days, and a half-life of 5.8 to 8.1 days

Research Context: Investigated in preclinical research models studying: Peptide selectivity Receptor binding characteristics Technical Information: Amino Acid Sequence: Aib-His-D-2-Nal-D-Phe-Lys-NH Amino Acid Length: 5 Molecular Weight: ~711 Da Form: Lyophilised powder Quantity: 5mg Storage & Handling: Store at -20C Handle using sterile laboratory technique Research Handling Note: For best results in a research setting, allow both: the peptide and chosen solvent to reach ambient laboratory temperature before reconstitution